TARSUS PHARMACEUTICALS INC. - COMMON STOCK

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

15 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

09 Nov 2022 06:00:03 By Nasdaq GlobeNewswire

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

25 Oct 2022 07:30:01 By Nasdaq GlobeNewswire

Tarsus Announces Transition Plans for Board of Directors

11 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

06 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

29 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings

27 Sep 2022 11:00:00 By Nasdaq GlobeNewswire

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

07 Sep 2022 06:00:02 By Nasdaq GlobeNewswire

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

11 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

05 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus to Present at the Jefferies 2022 Healthcare Conference

27 May 2022 08:00:00 By Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

10 May 2022 15:05:01 By Nasdaq GlobeNewswire

Tarsus to Present at Bank of America 2022 Healthcare Conference

06 May 2022 08:00:00 By Nasdaq GlobeNewswire

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

05 May 2022 07:30:01 By Nasdaq GlobeNewswire

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

03 May 2022 05:58:47 By Nasdaq GlobeNewswire

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

02 May 2022 06:01:00 By Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

02 May 2022 06:00:00 By Nasdaq GlobeNewswire

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

29 Apr 2022 20:23:30 By Nasdaq GlobeNewswire

Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting

26 Apr 2022 07:30:01 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

14 Mar 2022 15:05:00 By Nasdaq GlobeNewswire